Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?
Affiliation
Division of Cancer Sciences, University of Manchester, Manchester, UK.Issue Date
2020
Metadata
Show full item recordCitation
Phillips EH, Illidge TM. Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma? Br J Haematol. 2020.Journal
British Journal of HaematologyDOI
10.1111/bjh.16854PubMed ID
32557549Additional Links
https://dx.doi.org/10.1111/bjh.16854Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bjh.16854
Scopus Count
Collections
Related articles
- Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
- Authors: Matsuki E, Younes A
- Issue date: 2016 Jun
- Immune-Checkpoint Blockade Therapy in Lymphoma.
- Authors: Kuzume A, Chi S, Yamauchi N, Minami Y
- Issue date: 2020 Jul 30
- Noncellular Immune Therapies for Non-Hodgkin Lymphoma.
- Authors: Herrera AF
- Issue date: 2019 Aug
- Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors.
- Authors: Hwang SR, Higgins A, Castillo Almeida NE, LaPlant B, Maurer MJ, Ansell SM, Witzig TE, Thanarajasingam G, Bennani NN
- Issue date: 2021 Jan
- Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them.
- Authors: Savage KJ, Steidl C
- Issue date: 2016 Nov